新・泌尿器科臨床病理学

出版社: インターメディカ
著者:
発行日: 2015-04-01
分野: 臨床医学:外科  >  泌尿器科学
ISBN: 9784899963318
電子書籍版: 2015-04-01 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

11,000 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

商品紹介

臨床医が病理医から報告された所見を正しく理解し、治療に反映するためには、臨床医と病理医とのダイアローグによる「言葉」と「概念」の共有が必要不可欠である。病理学、泌尿器科学、分子生物学などの進歩によって加わった最新の知見や治療法を中心に、臨床最前線での27の“ホット”な疑問をQ&A形式で明快に解説する。

目次

  • 新・泌尿器科臨床病理学

    ―目次―

    I 腎癌
    Question 1
    2013年に腎腫瘍の新しい分類が提唱されたとの報告がありますが、
    それについて説明してください。2004年版のWHO分類とは
    どのように異なるのですか?

    Question 2
    管状嚢胞状腎細胞癌(tubulocystic renal cell carcinoma:
    TCRCC)について説明してください。
    その病理像は? その臨床的病態は?

    Question 3
    淡明細胞型乳頭状腎細胞癌(clear cell papillary renal cell
     carcinoma: CCPRCC)といわれる腎癌が最近文献でみられます。
    その生物学的特徴を解説してください。淡明細胞型腎細胞癌
    (clear cell renal cell carcinoma: CCRCC)や乳頭状腎細胞癌
    (papillary renal cell carcinoma: PRCC)と
    どのように異なるのですか?

    ほか

    II 膀胱癌
    Question 1
    2004年版WHO尿路上皮腫瘍分類の特徴の一つは、低悪性度乳頭状
    尿路上皮腫瘍の一部をPUNLMP(papillary urothelial neoplasm of
    low malignant potential)の名称で紹介したことですが、
    この疾患名は臨床家にとって、果たして有意義なものでしょうか?
    「腎盂・尿管・膀胱癌取扱い規約」では正式な診断項目として
    採用されていません。

    Question 2
    病期pT1尿路上皮腫瘍の性格について解説してください。
    進行癌に移行するタイプの特徴というものがありますか?

    Question 3
    pTa高異型度尿路上皮癌(urothelial carcinoma,high grade:
    CaHG、2004年版WHO分類)と初期診断された腫瘍の病態について
    説明してください。どのような臨床経過をたどりますか?

    ほか

    III  前立腺癌
    Question 1
    前立腺に被膜(capsule)はありますか? 泌尿器科医だけでなく
    病理医も、前立腺摘除検体の癌の進展度(stage)診断の際、
    “被膜”という言葉を使う傾向がありますが。

    Question 2
    前立腺の解剖学的構築について説明してください。
    泌尿器科医のみならず、外科病理医にとって重要な標識は何ですか?

    Question 3
    根治的前立腺摘除術(radical prostatectomy: RP)標本の
    病理学的検索により癌組織が前立腺外に浸潤していたり、
    外科的切除断端に進展していたという所見が報告されたとき、
    患者のその後の見通しはどうなりますか? このような結果でも
    術後に無治療で経過視察していると、前立腺特異抗原(prostate
    specific antigen: PSA)上昇がみられる患者と長期にわたり
    上昇がみられない患者とを経験します。
    病理学的に予知ができますか? また病理学的検索の結果、
    RPに成功したと思われていた患者の一部にPSA上昇がみられること
    もあります。病理医の立場からこの現象を説明してください。

    ほか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 腎癌

P.11 掲載の参考文献
P.15 掲載の参考文献
2. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008年.
9. Al-Hussain TO, Cheng L, Zhang S, Epstein JI. Tubulocystic carcinoma of the kidney with poorly differentiated foci : a series of 3 cases with fluorescence in situ hybridization analysis. Hum Pathol 2013, 44 : 1406-1411.
P.25 掲載の参考文献
1. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008年.
37. Delahunt B, Eble JN. Papillary renal cell carcinoma : a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997, 10 : 537-544.
P.29 掲載の参考文献
P.34 掲載の参考文献
2. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol 1995, 13 : 254-261.
P.41 掲載の参考文献
1. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008年.
10. Bensalah K, Pantuck AJ, Rioux-Leclercq N, and 46 other coauthors. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol 2010, 57 : 466-471.
17. Minervini A, Serni S, Tuccio A, Raspollini MR, Di Cristofano C, Siena G, Vittori G, Saleh O, Lapini A, Carini M. Local recurrence after tumour enucleation for renal cell carcinoma with no ablation of the tumour bed : results of a prospective single-centre study. BJU Int 2011, 107 : 1394-1399. (B)
26. Duvdevani M, Laufer M, Kastin A, Mor Y, Nadu A, Hanani J, Nativ O, Ramon J. Is frozen section analysis in nephron sparing surgery necessary? A clinicopathological study of 301 cases. J Urol 2005, 173 : 385-387.
28. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000, 75 : 1236-1242.
P.49 掲載の参考文献
13. Bosniak MA. Observation of small incidentally detected renal masses. Semin Urol Oncol 1995, 13 : 267-272. (A)
18. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol 2004, 11 : 2407-2410.
19. Wong JA, Rendon RA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can Urol Assoc J 2007, 1 : 120-122.

II 膀胱癌

P.59 掲載の参考文献
1. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008年.
2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, Lyon : IARC Press, 2004. p89.
4. 日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 : 泌尿器科・病理・放射線科 腎盂・尿管・膀胱癌取扱い規約. 金原出版, 2011.
12. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors : relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001, 165 : 1124-1130.
P.65 掲載の参考文献
P.68 掲載の参考文献
P.73 掲載の参考文献
2. Lopez-Knowles E, Hernandez S, Kogevinas M, Lloreta J, Amoros A, Tardon A, Carrato A, Kishore S, Serra C, Malats N, Real FX ; EPICURO Study Investigators. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006, 12 : 6029-6036.
6. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000, 9 : 2973-2980.
10. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995, 147 : 545-560.
11. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003, 1 : 1001-1008.
13. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994, 54 : 1169-1174.
18. Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S. p53 gene mutations in human urothelial carcinomas : analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 1995, 8 : 170-176.
19. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A. p53 mutations in human bladder cancer : genotypic versus phenotypic patterns. Int J Cancer 1994, 56 : 347-353.
21. Cote RJ, Dunn DM, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998, 58 : 1090-1094.
24. Presti JC Jr, Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991, 51 : 5405-5409.
25. Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, Benedict WF, Takahashi R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991, 51 : 5736-5743.
26. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57 : 1217-1221.
30. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001, 61 : 1265-1268.
34. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, Zwarthoff EC. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004, 64 : 1911-1914.
37. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002, 62 : 809-818.
P.78 掲載の参考文献
3. Lopez-Knowles E, Hernandez S, Kogevinas M, Lloreta J, Amoros A, Tardon A, Carrato A, Kishore S, Serra C, Malats N, Real FX ; EPICURO Study Investigators. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006, 12 : 6029-6036.
6. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965, 130 : 371-378.
P.85 掲載の参考文献
2. Wu XR, Manabe M, Yu J, Sun TT. Large scale purification and immunolocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. J Biol Chem 1990, 265 : 19170-19179.
4. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol 1995, 147 : 1383-1397.
14. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998, 110 : 385-390.
43. Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/ p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol 2013, 37 : 1815-1823.
44. Fellegara G, Gabba S, Dorji T, De Luca G, Colecchia M. Observations on Aron et al's "Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20/CD44s/ p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia." Am J Surg Pathol 2014, 38 : 1013-1015.
47. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008.

III 前立腺癌

P.93 掲載の参考文献
P.98 掲載の参考文献
P.103 掲載の参考文献
2. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996, 156 : 137-143.
9. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150 : 110-114.
13. Emerson RE, Koch MO, Jones TD, Doggy JK, Juliar BE, Cheng L. The influence of extent of surgical margin positivity on prostate specific antigen recurrence. J Clin Pathol 2005, 58 : 1028-1032.
18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostatespecific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 1996, 14 : 1770-1777.
22. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008.
40. Fesseha T, Sakr W, Grignon D, Banerjee M, Wood DP Jr, Pontes JE. Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol 1997, 158 : 2176-2179.
P.108 掲載の参考文献
P.113 掲載の参考文献
P.117 掲載の参考文献
21. Stamey TA, Yemoto CE. The clinical importance of separating transition zone (TZ) from peripheral (PZ) cancers. J Urol, 1998, 159 : 221. (C)
22. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable : a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000, 163 : 1155-1160.
P.123 掲載の参考文献
P.130 掲載の参考文献
6. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277 : 1445-1451.
7. Di Blasio CJ, Rhee AC, Cho D, Scardino PT, Kattan MW. Predicting clinical end points : treatment nomograms in prostate cancer. Semin Oncol 2003, 30 : 567-586.
P.135 掲載の参考文献
17. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelialmesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 2003, 63 : 3386-3394.
25. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52 : 5104-5109.
26. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54 3929-3933.
28. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res 2000, 60 : 3650-3654.
29. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000, 6 : 2295-2308.
P.143 掲載の参考文献
10. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000, 60 : 6134-6141.
11. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgenrefractory prostate cancer cells. Cancer Res 2002, 62 : 1008-1013.
14. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification : a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997, 57 : 314-319.
16. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61 : 2892-2898.
18. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59 : 2511-2515.
21. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR[ccr]) derived from an androgen-independent prostate cancer. J Med Chem 2002, 45 : 1439-1446.
22. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54 : 5474-5478.
28. Kwon OJ, Xin L. Prostate epithelial stem and progenitor cells. Am J Clin Exp Urol 2014, 2 : 209-218.
29. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52 : 6940-6944.
30. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993, 143 : 390-400.
31. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996, 2 : 389-398.
32. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995, 55 : 4438-4445.
38. Fan XJ, Wan XB, Yang ZL, Fu XH, Huang Y, Chen DK, Song SX, Liu Q, Xiao HY, Wang L, Wang JP. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelialmesenchymal transition in colorectal cancer. Hum Pathol 2013, 44 : 173-180.
39. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003, 63 : 2206-2215.
40. Weiss LM. Lymph Nodes. Cambridge University Press, 2008.
47. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000, 6 : 2104-2119.
P.150 掲載の参考文献
8. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283 : 845-848.
9. Kollet O, Spiegel A, Peled A, Petit I, Byk T, Hershkoviz R, Guetta E, Barkai G, Nagler A, Lapidot T. Rapid and efficient homing of human CD34 (+) CD38 (-/low) CXCR4 (+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m (null) mice. Blood 2001, 97 : 3283-3291.
14. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62: 1832-1837.
15. Jorgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res 1995, 55: 1817-1819.
P.159 掲載の参考文献
7. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008年.
P.164 掲載の参考文献
4. 大保亮一, 吉田修, 荒井陽一 : 日常臨床の疑問に答える 泌尿器科臨床病理学. インターメディカ, 2008.
5. Noordzij MA, van Weerden WM, de Ridder CM, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1996, 149 : 859-871.
7. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000, 60 : 741-748. (A)
8. Jongsma J, Oomen MH, Noordzji MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002, 50 : 203-215.
12. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostate carcinoma cell lines by serotonin antagonists. Anticancer Res 1994, 14 : 1215-1220.
16. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989, 63 : 1714-1720.
20. di Sant'Agnese PA. Calcitoninlike immunoreactive and bombesinlike immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 1986, 110 : 412-415.
25. Han K, Viallet J, Chevalier S, Zheng W, Bazinet M, Aprikian AG. Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells. Prostate 1997, 31 : 53-60.
26. Cox ME, Deeble PD, Lakhani S, Persons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible : implications for prostate cancer progression. Cancer Res 1999, 59 : 3821-3830.
P.172 掲載の参考文献
2. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980, 14 : 29-35.
3. Canadian Cancer Statistics 2000. National Cancer Institute of Canada, Toronto, Canada 2001.
5. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H. Mortality results from the Goteborg randomised populationbased prostate-cancer screening trial. Lancet Oncol 2010, 11 : 725-732.
10. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active surveillance program for prostate cancer : an update of the Johns Hopkins experience. J Clin Oncol 2011, 29 : 2185-2190.
11. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112 : 2664-2670.
19. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010, 28 : 2810-2816.
21. Kane CJ, Im R, Amling CK, Presti JC Jr, Aronson WJ, Terris MK, Freedland SJ ; SEARCH Database Study Group. Outcomes after radical prostatectomy among men who are candidates for active surveillance : results from the SEARCH database. Urology 2010, 76 : 695-700.

最近チェックした商品履歴

Loading...